Downregulation of MYO1C mediated by cepharanthine inhibits autophagosome-lysosome fusion through blockade of the F-actin network

Autor:	Qin Deng, Ning Gao, Ziyi Gao, Xiangyu Tang, Jinjiao Hu, Yanhao Zhang, Lirong Li, Xiuxing Jiang, Ruoqiu Fu, Yunong Li
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	0301 basic medicine Autophagosome-lysosome fusion Cancer Research Autophagosome maturation Benzylisoquinolines lcsh:RC254-282 Mass Spectrometry Myosin Type I 03 medical and health sciences chemistry.chemical_compound F-actin 0302 clinical medicine Cell Line Tumor Lysosome Mitophagy Autophagy Cepharanthine medicine Humans Gene knockdown LAMP1 Autophagy/Mitophagy Research Autophagosomes Colocalization Cepharanthine (CEP) lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Actins Cell biology 030104 developmental biology medicine.anatomical_structure Gene Expression Regulation Oncology chemistry 030220 oncology & carcinogenesis MYO1C Lysosomes Chromatography Liquid Protein Binding Signal Transduction
Zdroj:	Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-18 (2019) Journal of Experimental & Clinical Cancer Research : CR
ISSN:	1756-9966
DOI:	10.1186/s13046-019-1449-8
Popis:	Background MYO1C, an actin-based motor protein, is involved in the late stages of autophagosome maturation and fusion with the lysosome. The molecular mechanism by which MYO1C regulates autophagosome-lysosome fusion remains largely unclear. Methods Western blotting was used to determine the expression of autophagy-related proteins. Transmission electron microscopy (TEM) was used to observe the ultrastructural changes. An immunoprecipitation assay was utilized to detect protein-protein interactions. Immunofluorescence analysis was used to detect autophagosome-lysosome fusion and colocalization of autophagy-related molecules. An overexpression plasmid or siRNA against MYO1C were sequentially introduced into human breast cancer MDA-MB-231 cells. Results We show here that cepharanthine (CEP), a novel autophagy inhibitor, inhibited autophagy/mitophagy through blockage of autophagosome-lysosome fusion in human breast cancer cells. Mechanistically, we found for the first time that MYO1C was downregulated by CEP treatment. Furthermore, the interaction/colocalization of MYO1C and F-actin with either LC3 or LAMP1 was inhibited by CEP treatment. Knockdown of MYO1C further decreased the interaction/colocalization of MYO1C and F-actin with either LC3 or LAMP1 inhibited by CEP treatment, leading to blockade of autophagosome-lysosome fusion. In contrast, overexpression of MYO1C significantly restored the interaction/colocalization of MYO1C and F-actin with either LC3 or LAMP1 inhibited by CEP treatment. Conclusion These findings highlight a key role of MYO1C in the regulation of autophagosome-lysosome fusion through F-actin remodeling. Our findings also suggest that CEP could potentially be further developed as a novel autophagy/mitophagy inhibitor, and a combination of CEP with classic chemotherapeutic drugs could become a promising treatment for breast cancer.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88c3cb0148f4668b2617f78009070f63 http://link.springer.com/article/10.1186/s13046-019-1449-8 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.